Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I8B-MC-ITRO LY900014 vs Humalog in Type 1 Diabetes Using CSII
2015-005358-36Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of insulin lispro in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change in HbA1c from baseline to Week 16. Started Feb 2019; status: completed.
02
Drugs
insulin lispro
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2015-005358-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005358-36.